Dogwood Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.48 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.43Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $48.6M Enterprise Value $39M Shares Outstanding 37.1M diluted Next Earnings Date31 Oct 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Dogwood Therapeutics is a clinical-stage biopharmaceutical company focused on developing non-opioid treatments for pain and neuropathy. Its lead candidate, Halneuron, is a selective NaV 1.7 sodium channel blocker currently in a Phase 2b trial for chemotherapy-induced neuropathic pain (CINP). While interim data has shown encouraging separation from placebo, the company is pre-revenue and has a limited cash runway extending only into Q4 2026. Investors should maintain a Hold position pending the critical Phase 2b top-line data readout expected in Fall 2026, which will serve as a major binary catalyst for the stock. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$12.00 Mean target$14.00 High · most bullish analyst$15.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario Halneuron's Phase 2b trial fails to meet its primary endpoint of statistically significant pain reduction versus placebo, or reveals safety concerns that halt development. Given the company's limited cash runway and heavy reliance on Halneuron, a clinical failure would severely impair its valuation and force highly dilutive financing or restructuring. Base CaseCentral scenario The ongoing Phase 2b trial of Halneuron successfully completes enrollment and delivers statistically significant pain reduction compared to placebo in Fall 2026. This positive clinical outcome validates the NaV 1.7 mechanism, allowing Dogwood to secure a strategic partnership or raise capital on favorable terms to fund Phase 3 development. SP16 successfully initiates its Phase 1b trial. Bull CaseUpside scenario Successful Phase 2b readout for lead candidate Halneuron® in chemotherapy-induced neuropathic pain (CINP) expected in Fall 2026, which could serve as the basis for Phase 3 registration trials and unlock significant valuation upside. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |